MARKET

KYMR

KYMR

Kymera Therapeutics, Inc.
NASDAQ
108.12
-8.34
-7.16%
After Hours: 108.05 -0.07 -0.06% 19:11 06/26 EDT
OPEN
114.00
PREV CLOSE
116.46
HIGH
119.04
LOW
106.95
VOLUME
4.26M
TURNOVER
--
52 WEEK HIGH
130.05
52 WEEK LOW
36.65
MARKET CAP
8.89B
P/E (TTM)
-30.2874
1D
5D
1M
3M
1Y
5Y
1D
Major Investor Makes Dramatic Move in Kymera Therapeutics Holdings
TipRanks · 2d ago
BVF Partners reports Kymera Therapeutics share disposal worth $173.84 million
PUBT · 2d ago
Kymera Therapeutics Price Target Raised to $129.00/Share From $106.00 by Canaccord Genuity
Dow Jones · 2d ago
Kymera Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 2d ago
Canaccord Genuity Maintains Buy on Kymera Therapeutics, Raises Price Target to $129
Benzinga · 2d ago
B. Riley Securities Remains a Buy on Kymera Therapeutics (KYMR)
TipRanks · 2d ago
Kymera Therapeutics price target raised to $129 from $106 at Canaccord
TipRanks · 2d ago
Wells Fargo Keeps Their Buy Rating on Kymera Therapeutics (KYMR)
TipRanks · 2d ago
More
About KYMR
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral IRF5, degrader being developed for the treatment of rheumatic and autoimmune diseases.

Webull offers Kymera Therapeutics Inc stock information, including NASDAQ: KYMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYMR stock methods without spending real money on the virtual paper trading platform.